Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II studyAnna Maria Di Giacomo, Michele Maio, Paolo A. Ascierto et al.|Annals of Oncology|2014Cited by 139
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma IntergroupWilliam Bruno, Giovanna Bianchi‐Scarrà, Antonella Vecchiato et al.|Journal of the American Academy of Dermatology|2016Cited by 40
Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1Lorenza Pastorino, Paola Ghiorzo, Virginia Andreotti et al.|Cancers|2020Cited by 37
Survival in Patients With Sentinel Node–Positive Melanoma With Extranodal ExtensionAndrea Maurichi, Mario Santinami, Francesco Barretta et al.|Journal of the National Comprehensive Cancer Network|2021Cited by 7